Epstein R J
University Department of Clinical Oncology and Radiotherapeutics, Addenbrooke's Hospital, Cambridge.
Lancet. 1988 Mar 5;1(8584):521-4. doi: 10.1016/s0140-6736(88)91308-6.
Topoisomerases are DNA-modifying enzymes that are becoming increasingly important in clinical practice. These enzymes form a target for antibiotics, autoantibodies, and antitumour drugs, and may also be involved in the pathogenesis of certain genetic disorders. Strategies for clinical manipulation of these nuclear enzyme targets are discussed.